LONDON (Reuters) - Gilead’s remdesivir should not be used for patients hospitalised with COVID-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said on Friday.
“The ... panel found a lack of evidence that remdesivir improved outcomes that matter to patients,” the guideline said.
“Especially given the costs and resource implications associated with remdesivir ... the panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data,” it added.
The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.
The antiviral, known by the brand name Veklury, is one of only two medicines currently authorised to treat COVID-19 patients across the world. But a large WHO-led trial known as the Solidarity Trial showed last month that it had little or no effect on 28-day mortality or length of hospital stays for COVID-19 patients.
...
More:
https://www.reuters.com/article/us-h...-idUSKBN28000Q
Connect With Us